Dr. Kim Aalders comes to the EORTC from Utrecht, The Netherlands. Kim earned her Medical Degree from Utrecht University, The Netherlands and did her surgical residency at the Diakonessenhuis in Utrecht/Zeist. Since January 2014, she has also been a PhD Candidate in the Department of Surgery at Diakonessenhuis, where she is investigating prognostic aspects of breast cancer.
Kim joined the EORTC in September 2015 as Medical Research Fellow in the EORTC Breast Cancer Group. Here she will primarily be involved in a new project which is a substudy of the MINDACT trial (Microarray In Node negative Disease may Avoid ChemoTherapy): Dissecting the pathways of therapy resistance in early breast cancer.
Dr. Aalders will also be involved in various aspects of other EORTC breast cancer trials including AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?), the closed EORTC 10994-BCG P53 trial, and setting up the LORD trial (Exploring safety of avoiding aggressive treatment for low risk carcinoma that is confined to milk ducts of the breast, so called DCIS-Ductal Carcinoma in Situ).
Kim’s fellowship is supported by the EORTC Breast Cancer Group and the EORTC Cancer Research Fund.